1. Schirinzi T, Sciamanna G, Mercuri NB, Pisani A. Dystonia as a network disorder: a concept in evolution. Curr Opin Neurol. (2018) 31:498– 503. doi: 10.1097/WCO.0000000000000580
2. Naumann M, Pirker W, Reiners K, Lange KW, Becker G, Brucke T. Imaging the pre and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord. (1998) 13:319–23. doi: 10.1002/mds.870130219
3. Zoons E, Tijssen MAJ, Dreissen YEM, Speelman JD, Smit M, Booij J. The relationship between the dopaminergic system and depressive symptoms in cervical dystonia. Eur J Nucl Med Mol Imaging. (2017) 44:1375– 82. doi: 10.1007/s00259-017-3664-x
4. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by [123I]beta-CIT singlephoton emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol. (1998) 43:792–800. doi: 10.1002/ana.410 430614
5. Huang CC, Yen TC, Weng YH, Lu CS. Normal dopamine transporter binding in dopa responsive dystonia. J Neurol. (2002) 249:1016–20. doi: 10.1007/s00415-002-0776-3
6. Cáceres-Redondo MT, Carrillo F, Palomar FJ, Mir P. DYT-1 gene dystonic tremor presenting as a “scan without evidence of dopaminergic deficit.” Mov Disord. (2012) 27:1469. doi: 10.1002/mds.25171
7. Cilia R, Reale C, Castagna A, Nasca A, Muzi-Falconi M, Barzaghi C, et al. Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology. (2014) 83:1155– 62. doi: 10.1212/WNL.0000000000000821
8. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet. (1994) 8:236– 42. doi: 10.1038/ng1194-236
9. Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, et al. Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers. Brain. (2014) 137:2480–92. doi: 10.1093/brain/awu179
10. Lee WW, Jeon B, Kim R. Expanding the spectrum of Dopa-Responsive Dystonia (DRD) and proposal for new definition: DRD, DRD-plus, and DRD Look-alike. J Korean Med Sci. (2018) 33:e184. doi: 10.3346/jkms.2018.33.e184
11. Kidron D, Melamed E. Forms of dystonia in patients with Parkinson’s disease. Neurology. (1987) 37:1009–11. doi: 10.1212/WNL.37.6.1009
12. Shetty AS, Bhatia KP, Lang AE. Dystonia and Parkinson’s disease: what is the relationship? Neurobiol Dis. (2019) 132:104462. doi: 10.1016/j.nbd.2019.05.001
13. Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther. (2018) 7:233–48. doi: 10.1007/s40120-018-0105-0
14. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. (1998) 121:2053–66. doi: 10.1093/brain/121.11.2053
15. Iacono D, Geraci-Erck M, Peng H, Rabin ML, Kurlan R. Reduced number of pigmented neurons in the substantia nigra of dystonia patients? Findings from extensive neuropathologic, immunohistochemistry, and quantitative analyses. Tremor Other Hyperkinet Mov. (2015) 10:40. doi: 10.5334/tohm.241
16. McNaught KS, Kapustin A, Jackson T, Jengelley TA, Jnobaptiste R, Shashidharan P, et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol. (2004) 56:540–7. doi: 10.1002/ana.20225
17. Iacono D, Geraci-Erck M, Peng H, Rabin ML, Kurlan R. Hypertrophy of nigral neurons in Torsin1A deletion (DYT1) carriers manifesting dystonia. Parkinsonism Relat Disord. (2019) 58:63–9. doi: 10.1016/j.parkreldis.2018.08.020
18. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. NeuroReport. (2006) 17:1215– 8. doi: 10.1097/01.wnr.0000227984.84927.a7
19. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. (1997) 62:133–40. doi: 10.1136/jnnp.62.2.133
20. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VSC, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. (2013) 28:863–73. doi: 10.1002/mds.25475
21. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology. (1985) 35:73–7. doi: 10.1212/WNL.35.1.73
22. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. (2015) 30:1591–601. doi: 10.1002/mds.26424
23. Kawaguchi H, Shimada H, Kodaka F, Suzuki M, Shonotoh H, Hirano S, et al. Principal component analysis of multimodal neuromelanin MRI and dopamine transporter PET data provides a specific metric for the nigral dopaminergic neuronal density. PLoS ONE. (2016) 11:e0151191. doi: 10.1371/journal.pone.0151191
24. Nakata Y, Sakamoto A, Kawata A. Neuromelanin imaging analyses of the substantia nigra in patients with Machado–Joseph disease. Neuroradiology. (2020) 62:1433–9. doi: 10.1007/s00234-020-02479-9
25. Mukai M, Sugaya K, Yabe I, Goto Y, Yokochi F, Miyamoto K, et al. Neuromelanin MRI in a family with mitochondrial parkinsonism harboring a Y955C mutation in POLG1. Parkinsonism Relat Disord. (2013) 19:821– 4. doi: 10.1016/j.parkreldis.2013.04.011
26. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. (2006) 33:1491–9. doi: 10.1007/s00259-006-0155-x
27. Matsuda H, Murata M, Mukai Y, Sako K, Ono H, Toyama H, et al. Japanese multicenter database of healthy controls for [123I] FP-CIT SPECT. Eur J Nucl Med Mol Imaging. (2018) 45:1405–16. doi: 10.1007/s00259-018-3976-5
28. Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, et al. [123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys. (2017) 4:8. doi: 10.1186/s40658-017-0175-6
29. Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging. (2013) 40:565–73. doi: 10.1007/s00259-012-2304-8
30. Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. (2020) 47:1885–912. doi: 10.1007/s00259-020-04817-8
31. De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, et al. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse. (2003) 49:20– 8. doi: 10.1002/syn.10199
32. Pavese N, Tai YF. Nigrosome Imaging and neuromelanin sensitive MRI in diagnostic evaluation of Parkinsonism. Mov Disord Clin Pract. (2018) 5:131–40. doi: 10.1002/mdc3.12590
33. Kuya K, Ogawa T, Shinohara Y, Ishibashi M, Fujii S, Mukuda N, et al. Evaluation of Parkinson’s disease by neuromelanin-sensitive magnetic resonance imaging and 123I-FP-CIT SPECT. Acta Radiol. (2018) 59:593– 8. doi: 10.1177/0284185117722812
34. Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, et al. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson’s disease. Mov Disord. (2018) 33:1488– 92. doi: 10.1002/mds.27365
35. Sato K, Sumi-Ichinose C, Kaji R, Nomura T, Nagatsu I, Ichinose H, et al. Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci USA. (2008) 105:12551–6. doi: 10.1073/pnas.0806065105
36. Rose SJ, Yu XY, Heinzer AK, Harrast P, Fan X, Thompson VB, et al. A new knock-in mouse model of L-dopa-responsive dystonia. Brain. (2015) 138:2987–3002. doi: 10.1093/brain/awv212
37. Grötzsch H, Pizzolato GP, Ghika J, Schorderet D, Vingerhoets FJ, Landis T, et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology. (2002) 58:1839– 42. doi: 10.1212/WNL.58.12.1839
38. Segawa M, Nomura Y, Hayashi M. Dopa-responsive dystonia is caused by particular impairment of nigrostriatal dopamine neurons different from those involved in Parkinson disease: evidence observed in studies on Segawa disease. Neuropediatrics. (2013) 44:61–6. doi: 10.1055/s-0033- 1337337
39. Holton JL, Schneider SA, Ganesharajah T, Gandhi S, Strand C, Shashidharan P, et al. Neuropathology of primary adult-onset dystonia. Neurology. (2008) 70:695–9. doi: 10.1212/01.wnl.0000302175.76229.f0
40. Svetel M, Tomic A, Mijajlovi ´ c M, Dobricic V, Novakovic I, Pekmezovic T, et ´ al. Transcranial sonography in dopa-responsive dystonia. Eur J Neurol. (2017) 24:161–6. doi: 10.1111/ene.13172
41. Saunders-Pullman R, Stanley K, Brüggemann N, Raymond D, San Luciano M, Wang C, et al. Substantia nigra hyperechogenicity in DYT6 dystonia: a pilot study. Parkinsonism Relat Disord. (2010) 16:420– 2. doi: 10.1016/j.parkreldis.2010.03.003
42. Zhang Y, Zhang YC, Sheng YJ, Chen XF, Wang CS, Ma Q, et al. Sonographic alteration of basal ganglia in different forms of primary focal dystonia: a cross-sectional study. Chin Med J (Engl). (2016) 129:942– 5. doi: 10.4103/0366-6999.179792
43. Kojima K, Nakajima T, Taga N, Miyauchi A, Kato M, Matsumoto A, et al. Gene therapy improves motor and mental function of aromatic L-amino acid decarboxylase deficiency. Brain. (2019) 142:322–33. doi: 10.1093/brain/awy331
44. longi P, Iaccarino L, Perani D. PET Neuroimaging: insights on Dystonia andTourette Syndrome and Potential Applications. Front Neurol. (2014) 5:183. doi: 10.3389/fneur.2014. 00183
45. Bonsi P, Ponterio G, Vanni V, Tassone A, Sciamanna G, Migliarini S, et al. RGS9-2 rescues dopamine D2receptor levels and signaling in DYT1 dystonia mouse models. EMBO Mol Med. (2019)11:e9283. doi: 10.15252/emmm.201809283